Careers
Join Factor Bioscience and become part of a team working to invent new technologies to treat disease and improve health.
Our research lab and ISO Class 7 cleanroom facility are both located at our headquarters in Cambridge, Massachusetts.
Join Us
Associate Scientist
Factor Bioscience is seeking an exceptional candidate to join our team as Associate Scientist, Molecular Biology and Gene-Editing. This role is a part of the Molecular Biology team and supports development of Factor Bio’s novel UltraSlice gene-editing platform, as well as assisting optimization of nucleic acid delivery for pre-clinical programs. This is a lab-based position that works with state-of-the-art cell, molecular, and synthetic molecular biology techniques.
Factor News
October 17, 2024
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
Factor Bioscience Inc. (“Factor”) and Eterna Therapeutics Inc. (“Eterna”) today announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, […]
July 9, 2024
Factor Bioscience to Deliver Six Presentations at the International Society for Stem Cell Research (ISSCR) 2024 Annual Meeting
Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the International Society for Stem Cell Research (ISSCR) 2024 Annual Meeting to be held in Hamburg, Germany from July 10-13, 2024. Factor will deliver six presentations covering the latest preclinical data from Factor’s cell engineering platforms.
May 28, 2024
Factor Bioscience Successfully Defends Three U.S. Patents Covering Foundational Methods for Therapeutic Gene Editing
Factor Bioscience Inc., a Cambridge, Massachusetts-based biotechnology company pioneering mRNA-based cell engineering, today announced that the United States Patent and Trademark Office (USPTO) has terminated three separate ex parte reexaminations of three U.S. patents owned by Factor. These three patents, which, as a result of this action, remain in effect, relate to methods for producing gene-edited cells using mRNA encoding transcription activator-like effector nucleases (TALENs), a type of gene-editing protein.